Scilex Announces ZTlido® Insurance Coverage for ~100 Million Insured Lives(1)
January 14, 2019 07:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Scilex Pharmaceuticals Inc. (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE), today announced that ZTlido® (lidocaine topical system)...
Scilex Announces Addition of ZTlido® to Express Scripts National Formularies
January 14, 2019 07:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Scilex Pharmaceuticals Inc. (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE), today announced that Express Scripts has added ZTlido®...
Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing to Support the Commercialization of Non-Opioid ZTlido™ Pain Medication
September 10, 2018 04:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (“Sorrento”) announced today that its majority-owned subsidiary, Scilex Pharmaceuticals Inc. (“Scilex”),...
Hisamitsu America, Manufacturers of the Best-Selling Lidocaine Patch, Expand Lidocaine Line With New Cream and Roll-On Liquid Products
October 10, 2017 07:00 ET
|
Hisamitsu America
FLORHAM PARK, N.J., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Hisamitsu America, a division of Hisamitsu Pharmaceutical Co., Inc., and the manufacturers of the popular, unscented Salonpas® Lidocaine 4% Pain...